Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study-Reference-Cited by-同舟云学术

Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study

Published:2019-10-24 Issue:12 Volume:28 Page:1629-1639
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Adimadhyam Sruthi¹^ORCID,Lee Todd A.¹,Calip Gregory S.¹²³^ORCID,Smith Marsh Daphne E.⁴,Layden Brian T.⁵⁶,Schumock Glen T.¹

Affiliation:

1. Department of Pharmacy Systems, Outcomes and Policy, College of PharmacyUniversity of Illinois at Chicago Chicago IL USA

2. Center for Pharmacoepidemiology and Pharmacoeconomic ResearchUniversity of Illinois at Chicago Chicago IL USA

3. Epidemiology Program, Division of Public Health SciencesFred Hutchinson Cancer Research Center Seattle WA USA

4. Department of Pharmacy Practice, College of PharmacyUniversity of Illinois at Chicago Chicago IL USA

5. Division of Endocrinology, Diabetes and Metabolism, Department of MedicineUniversity of Illinois at Chicago Chicago IL USA

6. Jesse Brown Veterans Medical Center Chicago IL USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4900

Reference49 articles.

1. US Food and Drug Administration.Safety alerts for human medical products—Invokana and Invokamet (canagliflozin): Drug safety communication—New information on bone fracture risk and decreased bone mineral density.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm.

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

4. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis

5. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Fractures With Concomitant Use of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors;Annals of Pharmacotherapy;2023-12-11

2. Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis;Frontiers in Pharmacology;2023-11-06

3. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies;Frontiers in Pharmacology;2023-10-13

4. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease;Frontiers in Immunology;2023-09-21

5. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH;The Journal of Clinical Endocrinology & Metabolism;2023-09-20